1. Scrip
  2. >>Archive

Vertex unveils promising VX-222/Incivek combo data in HCV

 
• By Mike Ward

Vertex Pharmaceuticals has no plans to rest on its laurels in the treatment of HCV. Hot on the heels of getting FDA approval for Incivek (telaprevir), the oral HCV protease inhibitor developed in collaboration with the Janssen Pharmaceutical company Tibotec Virco (scripintelligence.com, 23 May 2011), the company has unveiled interim Phase II data highlighting the potential of VX-222, its lead hepatitis C virus polymerase inhibitor, as part of a combination approach to treating genotype-1 hepatitis C.

Vertex Pharmaceuticals has no plans to rest on its laurels in the treatment of HCV. Hot on the heels of getting FDA approval for Incivek (telaprevir), the oral HCV protease inhibitor developed in collaboration with the Janssen Pharmaceutical company Tibotec Virco (scripintelligence.com, 23 May 2011), the company has unveiled interim Phase II data highlighting the potential of VX-222, its lead hepatitis C virus polymerase inhibitor, as part of a combination approach to treating genotype-1 hepatitis C.

Interim data from the ongoing ZENITH Phase II study looking at the safety, tolerability and efficacy of VX-222, its lead hepatitisC virus polymerase inhibitor, with Incivek, Pegasys (pegylated alpha interferon)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By Jung Won Shin

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.